UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): October 31, 2006 (October 30, 2006)
REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| New York
|
|
000-19034
|
|
133444607 |
|
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number) |
| |
|
|
| 777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591-6707 |
| |
| (Address of principal executive offices)
|
|
(Zip Code) |
(914) 347-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On October 30, 2006, Regeneron Pharmaceuticals, Inc. announced
positive data from a Phase 3 clinical program designed to
provide two separate demonstrations of efficacy for the
investigational drug Interleukin-1 (IL-1) Trap (rilonacept)
within a single group of patients suffering from a rare chronic
disease known as CAPS (CIAS1-related autoinflammatorry periodic
syndromes). A copy of the press release is furnished as Exhibit
99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release dated October 30, 2006
2